The unique XPRESIDENT™ service combines mass spectrometry, genomics, biochemistry and immunology. Unlike others, we are able to identify tumor-associated peptides (TUMAPs) directly from primary human tumor material, so that TUMAPs are confirmed to be naturally processed and presented on real tumors removed by the surgeon and discarded otherwise.
If you would like to explore how you could benefit from the XPRESIDENT™ service through medical and scientific research, clinical trials, diagnosis and treatment of cancer, please contact us.
immatics biotechnologies GmbH
- Business Development Group -
For an off-the-shelf vaccine, TUMAPs need to be carefully selected:
(1) They should be shared by tumors in as many patients as possible,
(2) they should be characteristic for a certain type of cancer (e.g. colon cancer, breast cancer, etc.),
(3) they should be linked to a protein crucial for tumor survival and
(4) they should be able to elicit a strong immune response.
To accomplish this goal, immatics has developed its XPRESIDENT™ technology, which allows for a focused, effective and fast discovery of TUMAPs and their subsequent development to a vaccine.
Vaccine development starts with the identification of characteristic TUMAPs on tumor tissue from cancer patients which are then selected for their relevance, e.g. whether they are related to proteins that are essential for the survival of the cell, because such proteins cannot be easily replaced by the typical survival strategies of tumor cells. These TUMAPs are then investigated for their ability to induce the desired immune response. At the end of the process, a few dozen TUMAPs remain as promising candidates for use in a vaccine.
XPRESIDENT™ enables the detection of TUMAPs down to a femtomolar level - a so far unrivalled sensitivity level. The technology is able to identify several thousand TUMAPs per year and selects the most immunogenic antigens through a proprietary T-cell validation platform. The platform is scalable and can be applied to many different oncology indications.
immatics’ XPRESIDENT™ drug discovery platform is protected by issued European patents and world-wide patent applications. Recently, the EPO has granted patent protection for the identification, selection and validation of novel tumor-associated peptides (TUMAPs).
Due to its extremely high sensitivity, XPRESIDENT™ is a very efficient discovery engine with an unprecedented and extremely fast output of validated candidates for further clinical development.
In June 2009, immatics announced the completion of the next generation of XPRESIDENTTM. This significant step forward in immatics’ core technology platform allows for the first time the direct quantification of tumor-associated peptides (TUMAPs) presented on the surface of tumor cells in comparison to peptides presented on healthy tissues.